Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lulizumab pegol - Bristol-Myers Squibb

Drug Profile

Lulizumab pegol - Bristol-Myers Squibb

Alternative Names: BMS-931699; Lulizumab

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Monoclonal antibodies; Polyethylene glycols
  • Mechanism of Action CD28 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Renal transplant rejection
  • Discontinued Sjogren's syndrome; Systemic lupus erythematosus

Most Recent Events

  • 14 Sep 2023 Bristol-Myers Squibb and National Institute of Allergy and Infectious Diseases completes the phase-I/II CTOT-24 trial in Renal transplant rejection (Combination therapy, In adults, In the elderly) in USA (SC) (NCT04066114)
  • 22 Sep 2022 Bristol-Myers Squibb withdraws phase II trial in Renal transplant recipients and Kidney transplantation in US due to limited period of availability of a supply of the study drug and difficulties in enrollment in USA (NCT04903054)
  • 12 Apr 2021 Discontinued - Phase-II for Sjogren's syndrome in South Africa, Russia, Puerto Rico, Poland, Peru, Mexico, Italy, Chile, Australia, USA (SC) before April 2021 (Bristol-Myers Squibb website, April 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top